Eli LillyLLY
LLY
About: Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Employees: 47,000
0
Funds holding %
of 7,324 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
50% more first-time investments, than exits
New positions opened: 246 | Existing positions closed: 164
27% more repeat investments, than reductions
Existing positions increased: 1,763 | Existing positions reduced: 1,393
18% more funds holding in top 10
Funds holding in top 10: 327 [Q4 2024] → 385 (+58) [Q1 2025]
12% more capital invested
Capital invested by funds: $604B [Q4 2024] → $678B (+$73.3B) [Q1 2025]
4.66% more ownership
Funds ownership: 82.09% [Q4 2024] → 86.75% (+4.66%) [Q1 2025]
0% more funds holding
Funds holding: 3,850 [Q4 2024] → 3,852 (+2) [Q1 2025]
7% less call options, than puts
Call options by funds: $9.22B | Put options by funds: $9.88B
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$942
27%
upside
Avg. target
$1,042
40%
upside
High target
$1,135
52%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Guggenheim Seamus Fernandez | 27%upside $942 | Buy Maintained | 11 Jul 2025 |
Morgan Stanley Terence Flynn | 52%upside $1,135 | Overweight Maintained | 10 Jul 2025 |
UBS Trung Huynh | 41%upside $1,050 | Buy Maintained | 2 May 2025 |
Financial journalist opinion
Based on 78 articles about LLY published over the past 30 days
Positive
Zacks Investment Research
3 hours ago
Eli Lilly (LLY) Reports Next Week: Wall Street Expects Earnings Growth
Lilly (LLY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Positive
Market Watch
4 hours ago
10 stocks favored to gain up to 30% in a sector that has missed this year's rally
All but two of the S&P 500's sectors are up so far in 2025.
Positive
Benzinga
5 hours ago
Eli Lilly Obesity Drug Mounjaro Beats Legacy Trulicity On Cardio-Renal Health
Eli Lilly and Co. LLY released topline results from SURPASS-CVOT, a head-to-head Phase 3 cardiovascular outcomes trial comparing Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, to Trulicity (dulaglutide), a GLP-1 receptor agonist.
Positive
Barrons
6 hours ago
Elli Lilly Weight-Loss Drug Makes Cardio Advance. More Bad News for Novo Nordisk.
A Lilly study showed Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with the older drug Trulicity.
Positive
CNBC Television
7 hours ago
Eli Lilly's Mounjaro met goal of cardiovascular benefit in head-to-head trial with Trulicity
CNBC's Angelica Peebles joins 'Squawk Box' with the latest news from Eli Lilly.
Positive
Reuters
7 hours ago
Mounjaro proves more heart protective than Trulicity in trial of Eli Lilly diabetes drugs
Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling medication for the disease, in reducing the risk of heart attack and stroke in a large, head-to-head study.
Positive
CNBC
7 hours ago
Eli Lilly's Mounjaro shows heart health benefits in head-to-head trial with older diabetes drug Trulicity
Eli Lilly said its blockbuster diabetes drug Mounjaro showed similar heart health benefits as the company's older diabetes treatment, Trulicity, in a late-stage trial directly comparing the two medicines. The drugmaker said it believes the new data bolsters the case for Mounjaro to be prescribers' first choice for patients with Type 2 diabetes.
Neutral
PRNewsWire
7 hours ago
Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease
Mounjaro met the primary objective of non-inferiority vs. Trulicity with an 8% lower rate of MACE-3 events, while delivering greater reductions in A1C and weight In the trial, Mounjaro was associated with a 16% lower rate of all-cause death compared to Trulicity, suggesting more comprehensive health benefits Results from the largest and longest Mounjaro trial to date reaffirm its established safety and tolerability profile INDIANAPOLIS , July 31, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced topline results from SURPASS-CVOT, a first-of-its-kind head-to-head Phase 3 cardiovascular outcomes trial comparing two incretin therapies in adults with type 2 diabetes and established atherosclerotic cardiovascular disease.
Neutral
PRNewsWire
1 day ago
Lilly's Kisunla (donanemab-azbt) showed growing benefit over three years in early symptomatic Alzheimer's disease
Findings from the TRAILBLAZER-ALZ 2 long-term extension study highlight Kisunla continued to demonstrate slowing of decline, with most participants having completed treatment Data underscores the value of early intervention and supports a limited duration dosing approach with sustained long-term benefits INDIANAPOLIS , July 30, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced results from the long-term extension (LTE) of the Phase 3 TRAILBLAZER-ALZ 2 study showing that participants treated with Kisunla (donanemab-azbt) demonstrated slowing of decline, a benefit that continued to grow over three years compared to an untreated external cohort from the Alzheimer's Disease Neuroimaging Initiative (ADNI).1 Participants in the study who started treatment later still saw benefit. However, earlier initiation of Kisunla in study participants significantly reduced the risk of progression to the next stage of the disease compared to those who received Kisunla treatment later.1 These data were shared as a late breaking 2025 Alzheimer's Association International Conference (AAIC) presentation in Toronto.
Neutral
Zacks Investment Research
1 day ago
Eli Lilly (LLY) Declines More Than Market: Some Information for Investors
Eli Lilly (LLY) reached $762.95 at the closing of the latest trading day, reflecting a -5.59% change compared to its last close.
Charts implemented using Lightweight Charts™